Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Open-label Observation of Oral Hexavalent Reassorted Rotavirus Live Attenuated Vaccine (Vero Cell) in Healthy Adults and Children, as Well as the Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity in Healthy Infants

NCT06950645 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT06950645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06950645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Open-label Observation of Oral Hexavalent Reassorted Rotavirus Live Attenuated Vaccine (Vero Cell) in Healthy Adults and Children, as Well as the Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity in Healthy Infants
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 27, 2024
Completion date
December 18, 2025
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rotavirus gastroenteritis